# Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer

> **NCT02556762** · PHASE3 · UNKNOWN · sponsor: **Chuangzhen Chen** · enrollment: 202 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **RADIATION:** Radiotherapy with simultaneous modulated accelerated boost
- **RADIATION:** Standard dose radiotherapy
- **DRUG:** PF

## Key facts

- **NCT ID:** NCT02556762
- **Lead sponsor:** Chuangzhen Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2022-03-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556762, "Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02556762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*